Literature DB >> 17937464

Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome.

Michel Laroche1, Séverine Borg, Slim Lassoued, Brigitte De Lafontan, Henri Roché.   

Abstract

OBJECTIVE: Since the results of the ATAC study, women who have undergone surgery for breast cancer and who require adjuvant hormone therapy are often treated with aromatase inhibitors. With these treatments, joint pain is frequent (30% to 40%) and quite often disabling (5% to 10%). Our objective was to investigate the origin of the pain induced by the anti-aromatases.
METHODS: Twenty-four women of mean age 59 years with joint pain of > 5/10 on a visual analog scale underwent a rheumatological consultation and systematic laboratory tests.
RESULTS: In 5 patients, pain was considered to have a well defined cause: osteoarthritis, shoulder tendinitis, or paraneoplastic aponeurositis. The other 19 patients had inflammatory pain of the fingers, wrists, shoulders, forefeet, ankles, or knees, with slight synovial thickening of the PIP and MCP joints. Two had an inflammatory syndrome on laboratory tests. Nine of these patients had antinuclear antibodies (ANA > 1/160 on HEp-2 cells) and 4 had rheumatoid factors (> 20 U). Ten patients had sicca syndrome of the eyes or mouth, 7 had probable Sjögren's syndrome according to the San Diego criteria, and one had definite Sjögren's syndrome. One had rheumatoid arthritis, one had Hashimoto thyroiditis, and 2 had positive hepatitis C serology.
CONCLUSION: Is the almost total estrogen depletion induced by aromatase inhibitors conducive to the development of sicca syndromes with ANA? Our results should be considered in relation to the Sjögren-like syndromes occurring in aromatase knock-out mice as recently reported.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17937464

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  26 in total

1.  The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms.

Authors:  Victoria K Shanmugam; James McCloskey; Beth Elston; Sandra J Allison; Jennifer Eng-Wong
Journal:  Breast Cancer Res Treat       Date:  2011-11-11       Impact factor: 4.872

Review 2.  Drug-induced lupus erythematosus: incidence, management and prevention.

Authors:  Christopher Chang; M Eric Gershwin
Journal:  Drug Saf       Date:  2011-05-01       Impact factor: 5.606

3.  Defining the aromatase inhibitor musculoskeletal syndrome: a prospective study.

Authors:  Ora Singer; Tessa Cigler; Anne B Moore; Alana B Levine; Keith Hentel; Lily Belfi; Huong T Do; Lisa A Mandl
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-12       Impact factor: 4.794

4.  Sjögren's Syndrome is Associated With Reduced Lifetime Sex Hormone Exposure: A Case-Control Study.

Authors:  Sara S McCoy; Emmanuel Sampene; Alan N Baer
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-06-24       Impact factor: 4.794

5.  A case of anastrazole-related drug-induced autoimmune hepatitis.

Authors:  Mohammad Saiful Islam; Gavin Wright; Peter Tanner; Robert Lucas
Journal:  Clin J Gastroenterol       Date:  2014-07-22

6.  Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927.

Authors:  Dawn L Hershman; Joseph M Unger; Katherine D Crew; Danielle Awad; Shaker R Dakhil; Julie Gralow; Heather Greenlee; Danika L Lew; Lori M Minasian; Cathee Till; James L Wade; Frank L Meyskens; Carol M Moinpour
Journal:  J Clin Oncol       Date:  2015-05-04       Impact factor: 44.544

Review 7.  Estrogen and autoimmune disease.

Authors:  Sara E Walker
Journal:  Clin Rev Allergy Immunol       Date:  2011-02       Impact factor: 8.667

8.  Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study.

Authors:  N L Henry; D Pchejetski; R A'Hern; A T Nguyen; P Charles; J Waxman; L Li; A M Storniolo; D F Hayes; D A Flockhart; V Stearns; J Stebbing
Journal:  Br J Cancer       Date:  2010-07-06       Impact factor: 7.640

9.  Aromatase inhibitors associated musculoskeletal disorders and bone fractures in postmenopausal breast cancer patients: a result from Chinese population.

Authors:  Lu Xu; Jue Wang; Dan-Dan Xue; Wei He
Journal:  Med Oncol       Date:  2014-07-24       Impact factor: 3.064

10.  Insulin-like growth factor 1 and musculoskeletal pain among breast cancer patients on aromatase inhibitor therapy and women without a history of cancer.

Authors:  Lisa Gallicchio; Ryan MacDonald; Kathy J Helzlsouer
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-14       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.